Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients

Maria Addolorata Saracino, Athanasio Koukopoulos, Gabriele Sani, Mario Amore, Maria Augusta Raggi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

An original method based on the use of high-performance liquid chromatography with both coulometric and diode array detection has been developed for the therapeutic drug monitoring of patients with bipolar disorders being treated with olanzapine and lamotrigine. Chromatographic separation was achieved on a reversed-phase C8 column (150 × 4.6 mm internal diameter, 5 μm) using a mobile phase composed of methanol (27%) and a 50.0 mmol/L, pH 3.5 phosphate buffer (73%). For the analysis of olanzapine and its main metabolite, N-desmethylolanzapine, a coulometric detector was used, with electrode 1 set at -200 mV and electrode 2 at +500 mV. Lamotrigine was determined using a diode array detection at 220 nm. The two detectors were connected in series. For the analysis of biological samples, a clean-up procedure was implemented by means of solid-phase extraction using phenyl cartridges and eluting the analytes with methanol; only a small volume of plasma (150 μL) was needed to analyze both olanzapine and lamotrigine. Linear responses were obtained between 0.1 and 50.0 ng mL for olanzapine, 0.1 and 25.0 ng mL for N-desmethylolanzapine, and between 0.25 and 10.0 μg mL for lamotrigine. The extraction yield values were always higher than 90% for all the analytes, with precision (expressed as relative standard deviation values) lower than 3.4%. The method was applied successfully to some human plasma samples drawn from bipolar patients undergoing combined therapy with the two drugs. Satisfactory values for accuracy were obtained, with mean recovery higher than 91%. Thus, the method appears suitable for the investigation of the chemical-clinical correlations in patients receiving therapy with olanzapine and lamotrigine.

Original languageEnglish
Pages (from-to)773-780
Number of pages8
JournalTherapeutic Drug Monitoring
Volume29
Issue number6
DOIs
Publication statusPublished - Dec 2007

Fingerprint

olanzapine
Plasmas
Liquids
Methanol
Electrodes
Diodes
Plasma (human)
Detectors
Plasma Volume
Drug Monitoring
Solid Phase Extraction
High performance liquid chromatography
Metabolites
Bipolar Disorder
Pharmaceutical Preparations
Buffers
Phosphates
High Pressure Liquid Chromatography
lamotrigine
Recovery

Keywords

  • Lamotrigine
  • Liquid chromatography
  • Olanzapine
  • Plasma samples
  • Solid-phase extraction
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients. / Saracino, Maria Addolorata; Koukopoulos, Athanasio; Sani, Gabriele; Amore, Mario; Raggi, Maria Augusta.

In: Therapeutic Drug Monitoring, Vol. 29, No. 6, 12.2007, p. 773-780.

Research output: Contribution to journalArticle

Saracino, Maria Addolorata ; Koukopoulos, Athanasio ; Sani, Gabriele ; Amore, Mario ; Raggi, Maria Augusta. / Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients. In: Therapeutic Drug Monitoring. 2007 ; Vol. 29, No. 6. pp. 773-780.
@article{5427ceda01ed4825bbf5e0b304819eed,
title = "Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients",
abstract = "An original method based on the use of high-performance liquid chromatography with both coulometric and diode array detection has been developed for the therapeutic drug monitoring of patients with bipolar disorders being treated with olanzapine and lamotrigine. Chromatographic separation was achieved on a reversed-phase C8 column (150 × 4.6 mm internal diameter, 5 μm) using a mobile phase composed of methanol (27{\%}) and a 50.0 mmol/L, pH 3.5 phosphate buffer (73{\%}). For the analysis of olanzapine and its main metabolite, N-desmethylolanzapine, a coulometric detector was used, with electrode 1 set at -200 mV and electrode 2 at +500 mV. Lamotrigine was determined using a diode array detection at 220 nm. The two detectors were connected in series. For the analysis of biological samples, a clean-up procedure was implemented by means of solid-phase extraction using phenyl cartridges and eluting the analytes with methanol; only a small volume of plasma (150 μL) was needed to analyze both olanzapine and lamotrigine. Linear responses were obtained between 0.1 and 50.0 ng mL for olanzapine, 0.1 and 25.0 ng mL for N-desmethylolanzapine, and between 0.25 and 10.0 μg mL for lamotrigine. The extraction yield values were always higher than 90{\%} for all the analytes, with precision (expressed as relative standard deviation values) lower than 3.4{\%}. The method was applied successfully to some human plasma samples drawn from bipolar patients undergoing combined therapy with the two drugs. Satisfactory values for accuracy were obtained, with mean recovery higher than 91{\%}. Thus, the method appears suitable for the investigation of the chemical-clinical correlations in patients receiving therapy with olanzapine and lamotrigine.",
keywords = "Lamotrigine, Liquid chromatography, Olanzapine, Plasma samples, Solid-phase extraction, Therapeutic drug monitoring",
author = "Saracino, {Maria Addolorata} and Athanasio Koukopoulos and Gabriele Sani and Mario Amore and Raggi, {Maria Augusta}",
year = "2007",
month = "12",
doi = "10.1097/FTD.0b013e31815bde43",
language = "English",
volume = "29",
pages = "773--780",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients

AU - Saracino, Maria Addolorata

AU - Koukopoulos, Athanasio

AU - Sani, Gabriele

AU - Amore, Mario

AU - Raggi, Maria Augusta

PY - 2007/12

Y1 - 2007/12

N2 - An original method based on the use of high-performance liquid chromatography with both coulometric and diode array detection has been developed for the therapeutic drug monitoring of patients with bipolar disorders being treated with olanzapine and lamotrigine. Chromatographic separation was achieved on a reversed-phase C8 column (150 × 4.6 mm internal diameter, 5 μm) using a mobile phase composed of methanol (27%) and a 50.0 mmol/L, pH 3.5 phosphate buffer (73%). For the analysis of olanzapine and its main metabolite, N-desmethylolanzapine, a coulometric detector was used, with electrode 1 set at -200 mV and electrode 2 at +500 mV. Lamotrigine was determined using a diode array detection at 220 nm. The two detectors were connected in series. For the analysis of biological samples, a clean-up procedure was implemented by means of solid-phase extraction using phenyl cartridges and eluting the analytes with methanol; only a small volume of plasma (150 μL) was needed to analyze both olanzapine and lamotrigine. Linear responses were obtained between 0.1 and 50.0 ng mL for olanzapine, 0.1 and 25.0 ng mL for N-desmethylolanzapine, and between 0.25 and 10.0 μg mL for lamotrigine. The extraction yield values were always higher than 90% for all the analytes, with precision (expressed as relative standard deviation values) lower than 3.4%. The method was applied successfully to some human plasma samples drawn from bipolar patients undergoing combined therapy with the two drugs. Satisfactory values for accuracy were obtained, with mean recovery higher than 91%. Thus, the method appears suitable for the investigation of the chemical-clinical correlations in patients receiving therapy with olanzapine and lamotrigine.

AB - An original method based on the use of high-performance liquid chromatography with both coulometric and diode array detection has been developed for the therapeutic drug monitoring of patients with bipolar disorders being treated with olanzapine and lamotrigine. Chromatographic separation was achieved on a reversed-phase C8 column (150 × 4.6 mm internal diameter, 5 μm) using a mobile phase composed of methanol (27%) and a 50.0 mmol/L, pH 3.5 phosphate buffer (73%). For the analysis of olanzapine and its main metabolite, N-desmethylolanzapine, a coulometric detector was used, with electrode 1 set at -200 mV and electrode 2 at +500 mV. Lamotrigine was determined using a diode array detection at 220 nm. The two detectors were connected in series. For the analysis of biological samples, a clean-up procedure was implemented by means of solid-phase extraction using phenyl cartridges and eluting the analytes with methanol; only a small volume of plasma (150 μL) was needed to analyze both olanzapine and lamotrigine. Linear responses were obtained between 0.1 and 50.0 ng mL for olanzapine, 0.1 and 25.0 ng mL for N-desmethylolanzapine, and between 0.25 and 10.0 μg mL for lamotrigine. The extraction yield values were always higher than 90% for all the analytes, with precision (expressed as relative standard deviation values) lower than 3.4%. The method was applied successfully to some human plasma samples drawn from bipolar patients undergoing combined therapy with the two drugs. Satisfactory values for accuracy were obtained, with mean recovery higher than 91%. Thus, the method appears suitable for the investigation of the chemical-clinical correlations in patients receiving therapy with olanzapine and lamotrigine.

KW - Lamotrigine

KW - Liquid chromatography

KW - Olanzapine

KW - Plasma samples

KW - Solid-phase extraction

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=36549046650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549046650&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e31815bde43

DO - 10.1097/FTD.0b013e31815bde43

M3 - Article

C2 - 18043475

AN - SCOPUS:36549046650

VL - 29

SP - 773

EP - 780

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 6

ER -